Murrieta, CA – April 21st, 2017

When it comes to stool, sometimes less is more. A recent study published in the Journal of Clinical Microbiology titled “Evaluation of the New FecalSwab™ to Maintain Stability of Stool Samples Submitted for Molecular Tests” concluded that this is particularly true when taking advantage of the convenience and accuracy of COPAN’s latest product addition: FecalSwab™. The study, released on March 15, 2017 set out to determine the most effective, rapid and least invasive method to collect stool samples and quickly treat patients suffering from gastrointestinal diseases. 

Murrieta, CA May 5th, 2017

GI Pathogens can be difficult to detect due to the lack of sensitivity and speed experienced with traditional methods and patients having trouble providing a timely specimen. To help remedy these issues COPAN’s FecalSwab™ (FS) has been the focal point of several recent evaluations. As a kit, FecalSwab™ comes with a regular COPAN flocked swab (FLOQSwabs™) and 2 mL of Cary-Blair medium. Many clinicians have considered using the flocked swab as a rectal swab, in scenarios where timely access to a sample is crucial, and ability to collect a fresh stool is unmanageable. There is an unmet clinical need in pediatric settings when the patient shows up with acute symptoms and a sample needs to be immediately obtained for testing. In a continuation of an earlier study, Dr. Chapin and her team presented Comparison of Results Obtained with the FilmArray GI Panel Using Rectal Swabs and Cary-Blair Stool from Patients with Gastroenteritis in the Pediatric Emergency Dept., which entailed studying the use of FecalSwab™ as a rectal collection device that could be administered upon patient visit in conjunction with a widely accepted rapid detection assay, the FilmArray Gastrointestinal Panel (BioFire Diagnostics). While FecalSwab™ has had FDA clearance since Spring of 2015, the use of FS as a rectal swab collection device used in conjunction with a molecular FilmArray GI Panel has not been cleared by the FDA. 

Murrieta, CA April 28th, 2017

When you got it, flaunt it. It appears the use of FecalSwab™ is popping up everywhere.
A brandnew study presented at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria examined the use of FecalSwab™ for yet another major molecular diagnostic platform, the Seegene Allplex gastrointestinal multiplex PCR. In this study, Rebbapragada et al examined FecalSwab’s compatibility with the Seegene’s molecular chemistry, and FecalSwab’s convenience and utility when used with an automated pipetting platform employed within the assay. The study showed FecalSwab’s improved limit of detection when compared to traditional enteric transport media. 

22-25 April 2017
Vienna, Austria


Copan Italia SPA
Seleziona 1 candidato che sarà assegnatario di borsa di studio aziendale per il profilo di Tecnico specializzato sul tema dell’adaptive manufacturing applicato alle apparecchiature per esami di laboratorio.

2 - SEP - 2016 

COPAN SHOWCASE: A New Era for Crime Scene Sample Collection Devices

Tuesday 27th September 2016 - 5.30pm to 7.30pm
Hyatt Regency in Minneapolis, MN, Room Greenway H-J



12 - MAY - 2016
With the recent implementation of WASPLab™ and digital microbiology, COPAN Diagnostics, Inc. is pleased to announce a strategic alliance with TriCore Reference Laboratories.

23 - FEB - 2016
Although the system is compatible with most swab types, several customers have successfully validated the use of Copan FLOQSwabs™ with iSWAB - ID and have combined the products in their workflow for optimal results. We highly recommend the use of Copan FLOQSwabs™ with Mawi's iSWAB - ID sample collection system. 

17 - FEB - 2016
Murrieta, CA – COPAN Diagnostics, Inc. is pleased to announce groundbreaking results of a multi-center study titled “Automated Scoring of Chromogenic Media for the Detection of MRSA using the WASPLab Image Analysis Software” recently published in the Journal of Clinical Microbiology. The study performed by Faron et al (2015) is unique in its class, testing 57,690 samples and demonstrating that the WASPLab™ image analysis software can automatically detect and segregate positive from negative MRSA samples using chromogenic agar with a sensitivity of 100%, and a specificity of 90-96% (varying by location). In fact, the software was able to detect an additional 153 positive MRSA patients that were missed by manual reading. Locations of the participating laboratories spanned across the globe including Italy, The Netherlands, Canada, and the United States.

3 - SEP -2015
A recent study conducted at Tampa General Hospital in Florida, and published in the Journal of Clinical Microbiology, tested the use of ESwab™ with the BD Max MRSAXT and BD Max StaphSR assays. The study, consisting of 255 samples collected using ESwab™ showed that the assays have exceptional sensitivity and specificity for detecting MRSA and S. aureus, respectively.

Page 2 of 2